NCT05794386Recruiting
SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation
SCAR Burden of Left Atrium Guided cathEter Ablation sTrategy for Persistent Atrial Fibrillation (SCARLET-AF Study)
Source: ClinicalTrials.gov · Last updated 28 Apr 2026
Brief summary (registry, in English)
This is a multicenter, randomized controlled trial to compare the recurrence of 1-year atrial arrhythmia after catheter ablation of atrial fibrillation (AF) between pulmonary vein isolation (PVI) and PVI with additional left atrial (LA) substrate modification based on the left atrial low-voltage area (LA LVA) in patients with persistent AF who had a moderate burden of LVA in LA (1cm2 to \<30%).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 204 (estimated)
- First submitted
- 20 Mar 2023
- Start date
- 1 Feb 2023
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Seoul National University Hospital
- Diseases
- Atrial fibrillation
- NCT number
- NCT05794386
What you commit to
- Study type: Interventional
- Planned participants: 204
- From 1 Feb 2023 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with prior AF-related catheter ablation or surgery
- Patients with prior cardiac surgery
Other illness
- Patients with severe structural heart disease (severe mitral regurgitation, hypertrophy cardiomyopathy, other severe valvular heart diseases)
- Patients who had a myocardial infarction or underwent percutaneous coronary intervention within three months
- Patients who had a stroke or transient ischemic attack within 6 months
- Patients with intractable hypertension or uncontrolled thyroid disease
- Patients who need dialysis due to end-stage renal disease or who are scheduled for dialysis
- Patients who are taking immunosuppressive drugs or had undergone chemotherapy for cancer, autoimmune disease, transplant, etc
Lab values
- Known severe left ventricular systolic dysfunction (ejection fraction \<35%)
Other
- Patients with LA anteroposterior diameter of more than 55 mm
- Patients whose exact LVA burden cannot be calculated because high-quality 3D voltage mapping cannot be obtained during the procedure.
- Inability or unwillingness to receive anticoagulation (heparin or oral anticoagulation)
- Patients with intracardiac thrombus
- Patients who had a planned operation or procedure for the cardiovascular system
- Patients who are currently pregnant or are likely to be pregnant within the study period
- Patients whose life expectancy is less than 1 year
Who the study is looking for
- Patients with symptomatic persistent AF who undergo AF catheter ablation due to continued AF even after anti-arrhythmic agents or
- Patients with a burden of LA LVA (scar zone) of 1cm2 or more and less than 30% in 3D voltage mapping before the index catheter ablation are included in the randomized assignment group when performing catheter ablation in satisfaction with 1)
- 4\) Patients with an LVA of \<1cm2 or ≥30% are recruited as a registry.
Criteria the registry did not label
- Ages eligible for the study: 19 years or older
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Seoul National University Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.